A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
Sponsor: Incyte Corporation
A PHASE1 clinical study on Kidney Diseases and Renal Insufficiency, this trial is completed. The trial is conducted by Incyte Corporation and has accumulated 8 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2023 — May 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jun 2023 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .